Gujarat Kidney & Super Speciality Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Gujarat Kidney & Super Speciality Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹114
Per ShareLot Size
128 Shares
Minimum Investment
₹14,592
Issue Size
₹250.8 Cr
Face Value
₹2
Per ShareIPO Type
Book Building
Retail Quota
10%
QIB Quota
75%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Gujarat Kidney & Super Speciality Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
99.1%
Promoter Holding (Post-Issue)
71.45%
Issue Type
Book Building
ISIN
INE0V0W01025
About the Company
The Company is one of the regional healthcare companies located in the central region of state of Gujarat and operate a chain of midsized multispeciality hospitals, providing integrated healthcare services, with a focus on secondary and tertiary care. The Company, on a consolidated basis, operates seven (07) multispeciality hospitals and four (04) pharmacies operating within its Hospitals, Gujarat Kidney and Superspeciality Hospital (Vadodara), Gujarat Multispeciality Hospital (Godhra), Raj Palmland Hospital Private Limited (Bharuch), Surya Hospital and ICU (Borsad), Gujarat Surgical Hospital (Vadodara), Ashwini Medical Centre (Anand), Ashwini Medical Store (Anand) and Apex Multispeciality & Trauma Center (Bharuch) with a total bed capacity of 490 beds, approved bed capacity of 445 beds and operational bed capacity of 340 beds.
Industry Overview
As per the D&B Report, India has witnessed a notable increase in public spending on healthcare infrastructure, reflecting a growing commitment to bolstering the nation's healthcare system. Government health expenditure stood at approximately 1.9% of GDP in 2023-24, an increase from 1.28% in 2018-19. The government aims to raise this to 2.5% by 2025, as outlined in the National Health Policy. This upward trend indicates a prioritization of healthcare investment to address the evolving needs of the population. The public healthcare segment in India, while witnessing positive strides, continues to grapple with the demands of a vast and diverse population, necessitating sustained efforts and investments.
Company History
Gujarat Kidney And Super Speciality Limited (the "Issuer" or the "Company") was incorporated under the name and style of `Vihaan Medicare Private Limited', a private limited company under the Companies Act, 2013, pursuant to a certificate of incorporation dated December 20, 2019 issued by the Registrar of Companies, Central Registration Centre. Subsequently, in order to align its name with the business carried out by the Company of offering multi-speciality and super-speciality medical services, pursuant to a resolution passed by its Board of Directors in their meeting held on September 04, 2023, and by its Shareholders in an extraordinary general meeting held on September 06, 2023, the name of the Company was changed to `Gujarat Kidney and Super Speciality Private Limited' and a fresh certificate of incorporation dated September 13, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad. Further, the Company was converted into a public limited company pursuant to a resolution passed by its Board of Directors in their meeting held on November 02, 2023 and by its Shareholders in an extraordinary general meeting held on November 04, 2023 and consequently the name of the Company was changed to `Gujarat Kidney and Super Speciality Limited' and a fresh certificate of incorporation dated November 24, 2023 was issued by the Registrar of Companies, Gujarat at Ahmedabad.
Products & Services
- The Company is one of the regional healthcare companies located in the central region of state of Gujarat & operates a chain of midsized multispeciality hospitals, providing integrated healthcare services.
Growth Strategy
- Pursue strategic inorganic growth opportunities.
- Implementation of initiatives to improve existing operational efficiencies.
- Continue to recruit and retain skilled healthcare professionals.
- Strengthen its existing hospitals and its offerings and add new capabilities and specialties.
Customer Base
Wholesaler and Retailer
Financial Performance
Revenue, profit after tax and total assets across the last 3 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY23 to FY25.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Initial public offering of 2,20,00,000 equity shares of face value of Rs. 2 each ("Equity Shares") of the company for cash at a price of Rs. 108-Rs. 114 per equity share (including a share premium of Rs. 106-Rs. 112 per equity share) ("Issue Price") aggregating to Rs. 237.6-Rs. 250.80 crores ("Issue"). The issue shall constituted 27.90% of the post-issue paid-up equity share capital of the company. The face value of equity shares is ?2 each. the issue price was 57 times the face value of the equity shares. Bids can be made for a minimum of 128 equity shares and in multiples of 128 equity shares thereafter.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Pre-eminence in renal sciences, with established sub-superspecialties in urology and strong capabilities in other specialties.
- `Right-sized', full service and strategically located hospitals leading to high return on capital.
- Ability to attract, train and retain quality medical professionals.
- Investment in infrastructure, processes and clinical excellence driving affordability, and a strong value proposition for stakeholders.
- Track record of operating and financial performance and growth.
- The company proposes to use a portion of the Net Proceeds from the Issue for acquisition of Parekhs Hospital Private Limited, following which the Company will be responsible for overseeing and managing the Parekhs Hospital. Its may faces difficulties in completing the acquisition within the terms mentioned in term sheet, affecting the company future plans and prospects.
- The Company proposes to utilise a portion of the Net Proceeds from the Issue towards making part-payment of purchase consideration for the acquisition of Ashwini Medical Centre, pursuant to the Acquisition Agreement. In case of delay in raising funds from the Issue, its may face challenges in paying the consideration to sellers of Ashwini Medical Centre.
- The company proposed plans with respect to funding the capital expenditure requirement for construction of new hospital are subject to the risk of unanticipated delays in obtaining approvals and implementation which may adversely affect its business and results of operations. Further, the company are yet to place orders for such capital expenditure requirements. There is no assurance that its would be able to source such capital expenditure requirements in a timely manner or at commercially acceptable prices, which could adversely affect the company expansion plans. Its may be unsuccessful in implementing the company growth plans of expansion in Gujarat, India in a timely manner or at all, which may have an adverse effect on its business, financial condition and results of operations. Furthermore, the proposed construction of the new hospital is planned to be carried out on leased land, which includes potential challenges or risks related to the terms of lease arrangement, could have adverse effect on the company business, financial position, and results of operations.
- The Company has acquired Harmony Medicare Private Limited, subsequent to the three month period ended June 30, 2025. As its Company and Harmony Medicare Private Limited were separate entities operating independently from each other prior to June 30, 2025, the Restated Financial Statements does not include the financial information pertaining the said acquisition. Hence, the company Restated Financial Statements for the three month period ended June 30, 2025 and the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023, are not analogous and comparable to any future financial results/statements that its may prepare.
- The company is dependent on availability of nurses to provide quality healthcare services. A decline in the number of trained and available nurses may lead to a decline in its ability to provide required patient care and consequently adversely affect the company operations and performance.